PTO/SB/06a (05-07)
Approved for use through 09/09/207 OMS 0851-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE It os collection of information unless it contrars a valid OMS control number.

	Application Number		10723308		
	Filing Date		2003-11-26		
INFORMATION DISCLOSURE	First Named Inventor Chris		tian Gauguin Houghton		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		N/A		
	Examiner Name Not Y		t Yet Assigned		
	Attorney Docket Number	er	20517/100M285-US1		

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Code1 Issue Date Name of Patentee or Applicant Re			Releva		Lines where ges or Relev			
	1	4371513		1983-02	-01	MOISES G. SA	ANCHEZ				
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Document Re		Releva		Lines where ges or Relev	
	1	20020197321	A1	2002-12	-26	Seager					
	2	20020114833	A1	2002-08	-22	Abu-Izza et al.					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Applicant of cited		vhere Rel	or Relevant	TE
1	1	0057856	wo			2000-10-05 Pf Medicament et a		al.			×
2	2	2378383	GB			2003-02-12	Moonga Gursharan	,			Г

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10723308		
Filing Date		2003-11-26		
First Named Inventor	Christ	tian Gauguin Houghton		
Art Unit		N/A		
Examiner Name	Not Y	et Assigned		
Attomory Docket Numb	or	20517/100M285J1S1		

3	3	0278877	EP		1988-08-17	Medibrevex		×			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*											
	1	Hill, et al., 2001. "The ACVD task force on canine stopic dermatitis (IV): Environmental allergens". Verinary Immunology and immunopathology 81: 169 – 186.									
	2 Database WPI Section Ch, Week 197437 Derwent Publications Ltd. XP002257644, July 20, 1974, Abstract.										
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add										
	EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered										
*FXAMIN	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a										

See Kind Codes of USPTO Patent Documents at wine <u>USPTO_GOV</u> or MPEP 961.64. If Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). If Yes Jupanese patent documents, he indicates of the page of the trippeter must preced the senial number of the plaint document. See that the page of the page of the trippeter must preced the senial number of the plaint document. The page of the pag

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10723308		
Filing Date		2003-11-26		
First Named Inventor Christ		ian Gauguin Houghton		
Art Unit		N/A		
Examiner Name	Not Y	et Assigned		
Attorney Docket Number		20517/100M285-US1		

CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 02	to make	the	appropriate	colortion/s	'n

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97.0F.1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) in

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/FB/ Flynn Barrison (53,970)	Date (YYYY-MM-DD)	2007-06-27
Name - (Delet	Handre March avec Fillense	Decistostica Number	E40E0

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol field not by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.